MSH2 and cancer: CRC was the most frequent cancer (74% in path_MLH1 carriers and 66% in path_MSH2 carriers, chi-square test p = 0.3506) and extracolonic tumors were more recurrent in path_MSH2 carriers (Table 2 and Table 3).